“The relationship between an endpoint and an outcome is similar in many ways to the relationship between data and evidence,” explains Michael Lees, Head of Value, Evidence and Portfolio for Europe and Canada at Takeda Pharmaceutical Company Limited, and a program committee member for DIA’s Advancing the Science of Study Endpoints conference. “You can take a similar approach if you’re a clinical or regulatory expert: The transformation of the endpoint that’s measured in a clinical study into something that has meaning when you’re making a decision.”